Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma

What Are the Unanswered Questions?

Rajshekhar Chakraborty, Navneet S. Majhail, Faiz - Anwer

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
JournalJAMA Oncology
DOIs
StatePublished - Jan 1 2019

Fingerprint

zoledronic acid
Multiple Myeloma
Bone and Bones
Therapeutics
Denosumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma : What Are the Unanswered Questions? / Chakraborty, Rajshekhar; Majhail, Navneet S.; Anwer, Faiz -.

In: JAMA Oncology, 01.01.2019.

Research output: Contribution to journalComment/debate

@article{c9f7001e312043ccb3d9f97c149048e7,
title = "Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma: What Are the Unanswered Questions?",
author = "Rajshekhar Chakraborty and Majhail, {Navneet S.} and Anwer, {Faiz -}",
year = "2019",
month = "1",
day = "1",
doi = "10.1001/jamaoncol.2019.1598",
language = "English (US)",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",

}

TY - JOUR

T1 - Denosumab vs Zoledronic Acid for Bone-Targeted Therapy in Multiple Myeloma

T2 - What Are the Unanswered Questions?

AU - Chakraborty, Rajshekhar

AU - Majhail, Navneet S.

AU - Anwer, Faiz -

PY - 2019/1/1

Y1 - 2019/1/1

UR - http://www.scopus.com/inward/record.url?scp=85068319727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068319727&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2019.1598

DO - 10.1001/jamaoncol.2019.1598

M3 - Comment/debate

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

ER -